Good Life Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $643K | Sell |
13,893
-63,232
| -82% | -$3.1M | 0.04% | 271 |
|
|
2025
Q1 | $4.7M | Buy |
77,125
+10,404
| +16% | +$606K | 0.33% | 67 |
|
|
2024
Q4 | $3.77M | Buy |
66,721
+34,459
| +107% | +$1.93M | 0.27% | 77 |
|
|
2024
Q3 | $1.67M | Buy |
32,262
+16,689
| +107% | +$783K | 0.1% | 156 |
|
|
2024
Q2 | $647K | Sell |
15,573
-220
| -1% | -$9.84K | 0.05% | 216 |
|
|
2024
Q1 | $856K | Sell |
15,793
-999
| -6% | -$50.9K | 0.08% | 180 |
|
|
2023
Q4 | $862K | Sell |
16,792
-647
| -4% | -$34K | 0.09% | 172 |
|
|
2023
Q3 | $1.01M | Buy |
17,439
+2,239
| +15% | +$137K | 0.12% | 151 |
|
|
2023
Q2 | $972K | Buy |
15,200
+132
| +0.9% | +$8.85K | 0.11% | 152 |
|
|
2023
Q1 | $1.04M | Buy |
15,068
+114
| +0.8% | +$8.04K | 0.13% | 129 |
|
|
2022
Q4 | $1.08M | Sell |
14,954
-261
| -2% | -$19.7K | 0.15% | 131 |
|
|
2022
Q3 | $1.08M | Sell |
15,215
-246
| -2% | -$17.8K | 0.16% | 115 |
|
|
2022
Q2 | $1.19M | Sell |
15,461
-242
| -2% | -$18.4K | 0.17% | 115 |
|
|
2022
Q1 | $1.15M | Buy |
15,703
+477
| +3% | +$32K | 0.14% | 117 |
|
|
2021
Q4 | $949K | Sell |
15,226
-1,395
| -8% | -$81.8K | 0.12% | 137 |
|
|
2021
Q3 | $983K | Buy |
16,621
+40
| +0.2% | +$2.63K | 0.13% | 122 |
|
|
2021
Q2 | $1.11M | Buy |
16,581
+231
| +1% | +$15.1K | 0.21% | 88 |
|
|
2021
Q1 | $1.03M | Buy |
16,350
+854
| +6% | +$53.1K | 0.21% | 90 |
|
|
2020
Q4 | $960K | Sell |
15,496
-394
| -2% | -$24.2K | 0.22% | 81 |
|
|
2020
Q3 | $957K | Sell |
15,890
-700
| -4% | -$42.1K | 0.26% | 73 |
|
|
2020
Q2 | $979K | Buy |
16,590
+930
| +6% | +$55.6K | 0.29% | 68 |
|
|
2020
Q1 | $875K | Sell |
15,660
-6,460
| -29% | -$395K | 0.32% | 75 |
|
|
2019
Q4 | $1.42M | Buy |
22,120
+1,348
| +6% | +$77.2K | 0.4% | 51 |
|
|
2019
Q3 | $1.05M | Sell |
20,772
-474
| -2% | -$22.3K | 0.33% | 58 |
|
|
2019
Q2 | $964K | Sell |
21,246
-607
| -3% | -$28.3K | 0.28% | 60 |
|
|
2019
Q1 | $1.04M | Sell |
21,853
-65
| -0.3% | -$3.24K | 0.31% | 55 |
|
|
2018
Q4 | $1.14M | Buy |
21,918
+5,236
| +31% | +$281K | 0.37% | 52 |
|
|
2018
Q3 | $1.04M | Buy |
16,682
+674
| +4% | +$40K | 0.3% | 62 |
|
|
2018
Q2 | $884K | Buy |
16,008
+20
| +0.1% | +$1.08K | 0.28% | 66 |
|
|
2018
Q1 | $993K | Buy |
15,988
+198
| +1% | +$12.7K | 0.34% | 49 |
|
|
2017
Q4 | $979K | Sell |
15,790
-515
| -3% | -$32.2K | 0.3% | 60 |
|
|
2017
Q3 | $1.05M | Sell |
16,305
-405
| -2% | -$23.6K | 0.4% | 48 |
|
|
2017
Q2 | $935K | Sell |
16,710
-276
| -2% | -$15K | 0.41% | 53 |
|
|
2017
Q1 | $897K | Buy |
16,986
+3,963
| +30% | +$217K | 0.43% | 48 |
|
|
2016
Q4 | $743K | Buy |
+13,023
| New | +$712K | 0.43% | 44 |
|
Other funds holding BMY
Good Life Advisors's BMY Position: Q2 2025 in Review
Good Life Advisors reduced its Bristol-Myers Squibb (BMY) stake by 82% in Q2 2025, selling an estimated $3.1M and leaving 13,893 shares worth $643K. The position accounts for 0.04% of the portfolio, ranked #271.
Good Life Advisors first reported a position in BMY in Q4 2016 and has held it in 35 quarters since. The position peaked at $4.7M in Q1 2025. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Good Life Advisors held 13,893 shares of Bristol-Myers Squibb worth $643K as of Q2 2025.
- Good Life Advisors sold 63,232 Bristol-Myers Squibb shares in Q2 2025, an estimated $3.1M.
- Bristol-Myers Squibb made up 0.04% of Good Life Advisors's portfolio in Q2 2025, its #271 holding.
- Good Life Advisors first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 35 quarters since.
- Good Life Advisors's Bristol-Myers Squibb position peaked at $4.7M in Q1 2025.
- 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.